Literature DB >> 34933950

Effect of Chloroquine and Hydroxychloroquine on Cytokine Release Syndrome in Patients with COVID-19.

Bilal Ahmad1, Naeem Ul Hassan2, Bismillah Sehar3, Falak Zeb4, Dur E Nayab5, Fuad Ahmad Siddiqui2.   

Abstract

Objective: To assess the effect of chloroquine and hydroxychloroquine on cytokine release syndrome (CRS) in adult patients with coronavirus disease 2019 (COVID-19) having mild to moderate symptoms.
Methods: This blinded, placebo-controlled, randomized study was conducted in the Department of Medicine, Pak Emirates Military Hospital Rawalpindi, from June 1-15, 2020. A total of 150 hospitalized patients were enrolled after diagnoses with COVID-19 through reverse transcription polymerase chain reaction (RT-PCR). They were divided into three groups: hydroxychloroquine plus general care (HGC, n=50), chloroquine plus general care (CGC, n=50); and only general care (OGC, n=50). The HGC group received treatment with hydroxychloroquine 400 mg every 12 hours for day one and 200 mg for the next 4 days. The CGC group received treatment with chloroquine 250 mg every 12 hours for 7 days. The OGC group was kept as a control with only general care. After 12 days, the patients were screened for development of CRS through detection of interleukin 6 (IL-6) in serum samples by using Roche cobas e411 electrochemiluminescence immunoassay analyzer.
Results: The mean duration from onset of symptoms to randomization was 7.65 days (SD = 3.287 days; range, 2-15 days). The mean age of patients was 37.57 (range 19-63) years. Results showed that out of a total 150 patients, only 10 patients (6%, mean=1.93; CI=1.89-1.97, P=0.651) developed CRS in all study groups. Four patients (8%) developed CRS in the HGC group, 2 patients (4%) in the CGC group, and 4 patients (8%) in the OGC group. There was no significant difference in the mean level of CRS among study groups.
Conclusion: Administration of hydroxychloroquine and chloroquine has no effect in reducing the development of CRS in patients with COVID-19 having mild to moderate symptoms.
© 2021 Marshfield Clinic Health System.

Entities:  

Keywords:  COVID-19; Chloroquine; Coronavirus disease; Cytokine Release Syndrome; Hydroxychloroquine

Mesh:

Substances:

Year:  2021        PMID: 34933950      PMCID: PMC8691430          DOI: 10.3121/cmr.2021.1659

Source DB:  PubMed          Journal:  Clin Med Res        ISSN: 1539-4182


  10 in total

1.  The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy.

Authors:  Ronald B Melles; Michael F Marmor
Journal:  JAMA Ophthalmol       Date:  2014-12       Impact factor: 7.389

2.  Hydroxychloroquine use during the COVID-19 pandemic 2020.

Authors:  Heather G Mack
Journal:  Aust J Gen Pract       Date:  2020-04-14

3.  Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial.

Authors:  Wesley H Self; Matthew W Semler; Lindsay M Leither; Jonathan D Casey; Derek C Angus; Roy G Brower; Steven Y Chang; Sean P Collins; John C Eppensteiner; Michael R Filbin; D Clark Files; Kevin W Gibbs; Adit A Ginde; Michelle N Gong; Frank E Harrell; Douglas L Hayden; Catherine L Hough; Nicholas J Johnson; Akram Khan; Christopher J Lindsell; Michael A Matthay; Marc Moss; Pauline K Park; Todd W Rice; Bryce R H Robinson; David A Schoenfeld; Nathan I Shapiro; Jay S Steingrub; Christine A Ulysse; Alexandra Weissman; Donald M Yealy; B Taylor Thompson; Samuel M Brown; Jay Steingrub; Howard Smithline; Bogdan Tiru; Mark Tidswell; Lori Kozikowski; Sherell Thornton-Thompson; Leslie De Souza; Peter Hou; Rebecca Baron; Anthony Massaro; Imoigele Aisiku; Lauren Fredenburgh; Raghu Seethala; Lily Johnsky; Richard Riker; David Seder; Teresa May; Michael Baumann; Ashley Eldridge; Christine Lord; Nathan Shapiro; Daniel Talmor; Thomas O’Mara; Charlotte Kirk; Kelly Harrison; Lisa Kurt; Margaret Schermerhorn; Valerie Banner-Goodspeed; Katherine Boyle; Nicole Dubosh; Michael Filbin; Kathryn Hibbert; Blair Parry; Kendall Lavin-Parsons; Natalie Pulido; Brendan Lilley; Carl Lodenstein; Justin Margolin; Kelsey Brait; Alan Jones; James Galbraith; Rebekah Peacock; Utsav Nandi; Taylor Wachs; Michael Matthay; Kathleen Liu; Kirsten Kangelaris; Ralph Wang; Carolyn Calfee; Kimberly Yee; Gregory Hendey; Steven Chang; George Lim; Nida Qadir; Andrea Tam; Rebecca Beutler; Joseph Levitt; Jenny Wilson; Angela Rogers; Rosemary Vojnik; Jonasel Roque; Timothy Albertson; James Chenoweth; Jason Adams; Skyler Pearson; Maya Juarez; Eyad Almasri; Mohamed Fayed; Alyssa Hughes; Shelly Hillard; Ryan Huebinger; Henry Wang; Elizabeth Vidales; Bela Patel; Adit Ginde; Marc Moss; Amiran Baduashvili; Jeffrey McKeehan; Lani Finck; Carrie Higgins; Michelle Howell; Ivor Douglas; Jason Haukoos; Terra Hiller; Carolynn Lyle; Alicia Cupelo; Emily Caruso; Claudia Camacho; Stephanie Gravitz; James Finigan; Christine Griesmer; Pauline Park; Robert Hyzy; Kristine Nelson; Kelli McDonough; Norman Olbrich; Mark Williams; Raj Kapoor; Jean Nash; Meghan Willig; Henry Ford; Jayna Gardner-Gray; Mayur Ramesh; Montefiore Moses; Michelle Ng Gong; Michael Aboodi; Ayesha Asghar; Omowunmi Amosu; Madeline Torres; Savneet Kaur; Jen-Ting Chen; Aluko Hope; Brenda Lopez; Kathleen Rosales; Jee Young You; Jarrod Mosier; Cameron Hypes; Bhupinder Natt; Bryan Borg; Elizabeth Salvagio Campbell; R Duncan Hite; Kristin Hudock; Autumn Cresie; Faysal Alhasan; Jose Gomez-Arroyo; Abhijit Duggal; Omar Mehkri; Andrei Hastings; Debasis Sahoo; Francois Abi Fadel; Susan Gole; Valerie Shaner; Allison Wimer; Yvonne Meli; Alexander King; Thomas Terndrup; Matthew Exline; Sonal Pannu; Emily Robart; Sarah Karow; Catherine Hough; Bryce Robinson; Nicholas Johnson; Daniel Henning; Monica Campo; Stephanie Gundel; Sakshi Seghal; Sarah Katsandres; Sarah Dean; Akram Khan; Olivia Krol; Milad Jouzestani; Peter Huynh; Alexandra Weissman; Donald Yealy; Denise Scholl; Peter Adams; Bryan McVerry; David Huang; Derek Angus; Jordan Schooler; Steven Moore; Clark Files; Chadwick Miller; Kevin Gibbs; Mary LaRose; Lori Flores; Lauren Koehler; Caryn Morse; John Sanders; Caitlyn Langford; Kristen Nanney; Masiku MdalaGausi; Phyllis Yeboah; Peter Morris; Jamie Sturgill; Sherif Seif; Evan Cassity; Sanjay Dhar; Marjolein de Wit; Jessica Mason; Andrew Goodwin; Greg Hall; Abbey Grady; Amy Chamberlain; Samuel Brown; Joseph Bledsoe; Lindsay Leither; Ithan Peltan; Nathan Starr; Melissa Fergus; Valerie Aston; Quinn Montgomery; Rilee Smith; Mardee Merrill; Katie Brown; Brent Armbruster; Estelle Harris; Elizabeth Middleton; Robert Paine; Stacy Johnson; Macy Barrios; John Eppensteiner; Alexander Limkakeng; Lauren McGowan; Tedra Porter; Andrew Bouffler; J. Clancy Leahy; Bennet deBoisblanc; Matthew Lammi; Kyle Happel; Paula Lauto; Wesley Self; Jonathan Casey; Matthew Semler; Sean Collins; Frank Harrell; Christopher Lindsell; Todd Rice; William Stubblefield; Christopher Gray; Jakea Johnson; Megan Roth; Margaret Hays; Donna Torr; Arwa Zakaria; David Schoenfeld; Taylor Thompson; Douglas Hayden; Nancy Ringwood; Cathryn Oldmixon; Christine Ulysse; Richard Morse; Ariela Muzikansky; Laura Fitzgerald; Samuel Whitaker; Adrian Lagakos; Roy Brower; Lora Reineck; Neil Aggarwal; Karen Bienstock; Michelle Freemer; Myron Maclawiw; Gail Weinmann; Laurie Morrison; Mark Gillespie; Richard Kryscio; Daniel Brodie; Wojciech Zareba; Anne Rompalo; Michael Boeckh; Polly Parsons; Jason Christie; Jesse Hall; Nicholas Horton; Laurie Zoloth; Neal Dickert; Deborah Diercks
Journal:  JAMA       Date:  2020-12-01       Impact factor: 56.272

Review 4.  Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies.

Authors:  Julie Dyall; Robin Gross; Jason Kindrachuk; Reed F Johnson; Gene G Olinger; Lisa E Hensley; Matthew B Frieman; Peter B Jahrling
Journal:  Drugs       Date:  2017-12       Impact factor: 9.546

5.  Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.

Authors:  Wei Tang; Zhujun Cao; Mingfeng Han; Zhengyan Wang; Junwen Chen; Wenjin Sun; Yaojie Wu; Wei Xiao; Shengyong Liu; Erzhen Chen; Wei Chen; Xiongbiao Wang; Jiuyong Yang; Jun Lin; Qingxia Zhao; Youqin Yan; Zhibin Xie; Dan Li; Yaofeng Yang; Leshan Liu; Jieming Qu; Guang Ning; Guochao Shi; Qing Xie
Journal:  BMJ       Date:  2020-05-14

6.  [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].

Authors:  Jun Chen; Danping Liu; Li Liu; Ping Liu; Qingnian Xu; Lu Xia; Yun Ling; Dan Huang; Shuli Song; Dandan Zhang; Zhiping Qian; Tao Li; Yinzhong Shen; Hongzhou Lu
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-05-25

7.  COVID-19: consider cytokine storm syndromes and immunosuppression.

Authors:  Puja Mehta; Daniel F McAuley; Michael Brown; Emilie Sanchez; Rachel S Tattersall; Jessica J Manson
Journal:  Lancet       Date:  2020-03-16       Impact factor: 79.321

Review 8.  Pharmacotherapy in COVID-19; A narrative review for emergency providers.

Authors:  Nikita Mehta; Maryann Mazer-Amirshahi; Nour Alkindi; Ali Pourmand
Journal:  Am J Emerg Med       Date:  2020-04-15       Impact factor: 2.469

9.  A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.

Authors:  Bin Cao; Yeming Wang; Danning Wen; Wen Liu; Jingli Wang; Guohui Fan; Lianguo Ruan; Bin Song; Yanping Cai; Ming Wei; Xingwang Li; Jiaan Xia; Nanshan Chen; Jie Xiang; Ting Yu; Tao Bai; Xuelei Xie; Li Zhang; Caihong Li; Ye Yuan; Hua Chen; Huadong Li; Hanping Huang; Shengjing Tu; Fengyun Gong; Ying Liu; Yuan Wei; Chongya Dong; Fei Zhou; Xiaoying Gu; Jiuyang Xu; Zhibo Liu; Yi Zhang; Hui Li; Lianhan Shang; Ke Wang; Kunxia Li; Xia Zhou; Xuan Dong; Zhaohui Qu; Sixia Lu; Xujuan Hu; Shunan Ruan; Shanshan Luo; Jing Wu; Lu Peng; Fang Cheng; Lihong Pan; Jun Zou; Chunmin Jia; Juan Wang; Xia Liu; Shuzhen Wang; Xudong Wu; Qin Ge; Jing He; Haiyan Zhan; Fang Qiu; Li Guo; Chaolin Huang; Thomas Jaki; Frederick G Hayden; Peter W Horby; Dingyu Zhang; Chen Wang
Journal:  N Engl J Med       Date:  2020-03-18       Impact factor: 91.245

10.  In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

Authors:  Xueting Yao; Fei Ye; Miao Zhang; Cheng Cui; Baoying Huang; Peihua Niu; Xu Liu; Li Zhao; Erdan Dong; Chunli Song; Siyan Zhan; Roujian Lu; Haiyan Li; Wenjie Tan; Dongyang Liu
Journal:  Clin Infect Dis       Date:  2020-07-28       Impact factor: 9.079

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.